<DOC>
	<DOCNO>NCT01204827</DOCNO>
	<brief_summary>Patients HBeAg negative chronic HBV evidence hepatic disease ( elevate liver enzymes evidence cirrhosis ) significant viremia treat anti HBV therapy . Currently key goal anti HBV therapy profound prolong viral suppression treatment efficacy assess monitoring viral load liver enzyme . However always reflect degree liver impairment degree improvement response therapy . Sebivo accept Israel first line therapy HBeAg negative HBeAg positive chronic HBV evidence liver damage . Viral load decrease 1 log every 3 month , otherwise patient offer add-on alternative therapy . As majority patient Israel HBeAg negative chronic HBV order homogenous population select study patient HBeAg negative chronic HBV . The 13C Methacetin breath test , ass liver function specifically function microsomal CYP4501A2 . It show correlate degree liver impairment clinical outcome acute chronic liver disease . The aim study determine utility 13C Methacetin Breath Test follow patient HBeAg negative chronic HBV receive anti viral therapy .</brief_summary>
	<brief_title>Follow Up Patients Chronic Hepatitis B ( CHB ) Treated With Sebivo Using 13C Methacetin Breath Test</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>1 . Male female , least 18 year age . 2 . Documented chronic hepatitis B ( CHB ) infection define follow : Clinical history compatible CHB HBeAg negative chronic hepatitis B patient Detectable serum HBsAg least 6 month prior screen Serum HBV DNA level ≥ 2000 IU/mL determine either Abbott Roche Taqman assay Screening visit For patient cirrhosis , clinical history lab test compatible compensate liver disease Elevated serum ALT level &gt; x 1 ULN &lt; x 10 ULN ) Screening visit ( ULN 30 IU/mL ) If ALT level ≤ x 1 ULN must available liver histology report within 12 month screen indicate chronic hepatitis . If available , liver biopsy require baseline . 3 . Patient willing able comply study drug regimen study requirement . 4 . The patient willing able provide write informed consent participate study . 1 . History hypersensitivity study drug ( Methacetin , Sebivo ) drug similar chemical structure , include allergy paracetamol . 2 . Patient pregnant breastfeeding . 3 . Women childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean . The exception aforementioned criterion give meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/ml ( IU/L ) 6 week post surgical bilateral oophorectomy without hysterectomy surgically sterilize ( e.g. , bilateral tubal ligation ) patient must agree use two method birth control . This combination hormonal contraception ( implantable , patch , oral injection ) , IUD , male female condom spermicidal gel , diaphragm , sponge cervical cap . Women childbearing potential must negative serum betahuman chorionic gonadotropin ( βHCG ) 4 . Males capable reproduction , define men physiologically capable produce sperm , include men whose career , lifestyle , sexual orientation precludes intercourse female partner UNLESS female partner meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/ml ( IU/L ) patient must agree use two method birth control . This combination hormonal contraception ( implantable , patch , oral injection ) , IUD , male female condom spermicidal gel , diaphragm , sponge cervical cap . 5 . Patient coinfected HCV , HDV , HIV . 6 . Severe uncontrolled disease organ ( heart , kidney , lung ) . 7 . Patients previously involve trial telbivudine . 8 . Patient receive nucleoside nucleotide drug whether approve investigational time . 9 . Patient receive IFN immunomodulatory treatment 6 month Screening study . 10 . Patient history clinical signs/symptoms hepatic decompensation ascites , esophageal variceal bleeding , hepatic encephalopathy , hepatorenal syndrome , hepatic hydrothorax , hepatopulmonary syndrome spontaneous bacterial peritonitis , among others . 11 . Patient medical condition require prolonged frequent use systemic acyclovir famciclovir . 12 . Patient history malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . Patients previous finding suggestive possible hepatocellular carcinoma ( HCC ) , disease rule prior entrance study . 13 . Patient one additional know primary secondary cause liver disease CHB , include steatohepatitis autoimmune hepatitis among liver disease . Gilbert 's syndrome DubinJohnson syndrome consider exclusion criterion study . 14 . History acute chronic medical condition opinion investigator would make patient unsuitable inclusion study . 15 . Patient currently abuse alcohol illicit drug , history alcohol abuse illicit substance abuse within precede two year . 16 . Patient medical condition require frequent prolong use systemic corticosteroid , although inhaled corticosteroid allow . 17 . Patient history clinical laboratory evidence chronic renal insufficiency ( Estimated calculate serum creatinine clearance &lt; 50 ) 18 . Patient medical condition require chronic prolong use potentially hepatotoxic drug nephrotoxic drug . 19 . Patient concurrent medical social condition likely preclude compliance schedule evaluation protocol , likely confound efficacy safety observation study . 20 . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer . 21 . Patient history myopathy , myositis , persistent muscle weakness . 22 . Patient follow laboratory value Screening : Hemoglobin &lt; 11 g/dL ( 110 g/L ) men &lt; 10 g/dL ( 100 g/L ) woman Total WBC &lt; 3,500/mm3 ( 3.5 x 109/Liter ) Absolute neutrophil count ( ANC ) &lt; 1,500/mm3 ( 1.5 x 109/Liter ) Platelet count &lt; 75,000/mm3 ( 75 x 109/Liter ) Serum amylases lipase ≥ 1.5 x ULN Serum albumin &lt; 3.3 g/dL ( 33g/L ) Total bilirubin ≥ 2.0 mg/dL ( 34.2 μmol/L ) Estimated calculated serum creatinine clearance &lt; 50 mL/min ( 0.48 ml/s ) use CockcroftGault method lean ideal body weight ; see Glossary Terms ( Cockcroft 1976 ) AFP &gt; 50 ng/mL μg/L ( require work per local medical standard ) 23 . Patient fast 8 hour . 24 . Patient smoke day test . 25 . Patient take drug interfere methacetin metabolism : fluvoxamine , amiodarone , ciprofloxacin , cimetidine , rifampin , carbamazepine within last 24 hour . 26 . Patient take Tylenol acetaminophen relate medication within past 24 hour . 27 . Patients receive new medication last 48 hour . 28 . Patients still suffer previous clinical intervention ( e.g . biopsy ) 29 . Patients consume alcohol 24 hour prior MBT consume alcohol regular basis 40gr male 20gr female per day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Patients chronic HBeAg negative hepatitis B virus infection treat Sebivo ( Telbivudine )</keyword>
</DOC>